Genomics Growth
搜索文档
Tempus AI signals sustained 25% genomics growth target through 2028 while achieving first positive adjusted EBITDA (NASDAQ:TEM)
Seeking Alpha· 2025-11-05 08:07
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...